↓ Skip to main content

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Overview of attention for article published in Lancet Neurology, January 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
29 X users
patent
9 patents
facebook
4 Facebook pages
googleplus
3 Google+ users
reddit
1 Redditor

Citations

dimensions_citation
530 Dimensions

Readers on

mendeley
472 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
Published in
Lancet Neurology, January 2012
DOI 10.1016/s1474-4422(11)70305-2
Pubmed ID
Authors

Peter Connick, Madhan Kolappan, Charles Crawley, Daniel J Webber, Rickie Patani, Andrew W Michell, Ming-Qing Du, Shi-Lu Luan, Daniel R Altmann, Alan J Thompson, Alastair Compston, Michael A Scott, David H Miller, Siddharthan Chandran

Abstract

More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need. On the basis of evidence that mesenchymal stem cells have a beneficial effect in acute and chronic animal models of multiple sclerosis, we aimed to assess the safety and efficacy of these cells as a potential neuroprotective treatment for secondary progressive multiple sclerosis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 472 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 4 <1%
Germany 2 <1%
Brazil 2 <1%
Turkey 1 <1%
Netherlands 1 <1%
Portugal 1 <1%
Sweden 1 <1%
South Africa 1 <1%
Korea, Republic of 1 <1%
Other 4 <1%
Unknown 454 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 78 17%
Researcher 64 14%
Student > Bachelor 59 13%
Student > Master 58 12%
Student > Doctoral Student 24 5%
Other 95 20%
Unknown 94 20%
Readers by discipline Count As %
Medicine and Dentistry 131 28%
Agricultural and Biological Sciences 66 14%
Biochemistry, Genetics and Molecular Biology 53 11%
Neuroscience 28 6%
Engineering 23 5%
Other 51 11%
Unknown 120 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2023.
All research outputs
#856,347
of 25,411,814 outputs
Outputs from Lancet Neurology
#539
of 4,012 outputs
Outputs of similar age
#4,867
of 248,829 outputs
Outputs of similar age from Lancet Neurology
#4
of 54 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,012 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,829 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.